---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001693"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:49:40.364241+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# uniQure secures FDA Accelerated Approval pathway for AMT-130; 2024 net loss $239.6M

## Summary
- FDA agreed data from Phase I/II AMT-130 studies vs external control may support BLA; cUHDRS as intermediate endpoint, NfL as supportive.
- Cash and equivalents $367.5M at Dec 31, 2024; plus $80.7M net from public offering, funds operations into H2 2027.
- Net loss $239.6M ($4.92 loss per share) for 2024, vs $308.5M loss in 2023; revenues $27.1M up from $15.8M.
- Completed enrollment in third cohort of AMT-130 Phase I/II; initial safety update expected Q2 2025.
- Restructuring and sale of Lexington facility reduced workforce by ~65%, cut cash burn ~$70M/year.

## SEC filing metadata
- accession: 0001558370-25-001693
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/0001558370-25-001693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001693
- JSON: https://secwatch.observer/filing/0001558370-25-001693.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001693.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.